MedPath

Investigation of efficacy and safety of lanthanum carbonate in hyperphosphatemia patients treated with cinacalcet hydrochloride

Phase 4
Conditions
Hyperphosphatemia patients treated with cinacalcet hydrochloride for secondary hyperparathyroidism
Registration Number
JPRN-UMIN000002481
Lead Sponsor
Shigei medical research hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

1)Pts who meet the contraindiation criteria in package insert of lanthanum carbonate 2)Pregnant or possibly pregnant pts, pts on lactation 3)Inappropriate pts for this study according to the investigator's judgment

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum phosphate level
Secondary Outcome Measures
NameTimeMethod
1. Corrected serum calcium, serum calcium phosphorus product, intact PTH 2. Adverse events 3. Drug compliance
© Copyright 2025. All Rights Reserved by MedPath